Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA, Schmiegelow K, Albertsen BK, Prunsild K, Zeller B, Vaitkeviciene G, Abrahamsson J, Heyman M, Taskinen M, Harila-Saari A, Kanerva J, Frandsen TL; Nordic Society of Paediatric Haematology and Oncology (NOPHO) group. Raja RA, et al. Among authors: heyman m. Br J Haematol. 2014 Apr;165(1):126-33. doi: 10.1111/bjh.12733. Epub 2014 Jan 15. Br J Haematol. 2014. PMID: 24428625 Free article.
In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia.
Ramakers-van Woerden NL, Pieters R, Slater RM, Loonen AH, Beverloo HB, van Drunen E, Heyman M, Moreno TC, Rots MG, van Wering ER, Kamps WA, Janka-Schaub GE, Veerman AJ. Ramakers-van Woerden NL, et al. Among authors: heyman m. Br J Haematol. 2001 Mar;112(3):680-90. doi: 10.1046/j.1365-2141.2001.02586.x. Br J Haematol. 2001. PMID: 11260073 Free article.
Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92.
Calero Moreno TM, Gustafsson G, Garwicz S, Grandér D, Jonmundsson GK, Frost BM, Mäkipernaa A, Rasool O, Savolainen ER, Schmiegelow K, Söderhäll S, Vettenranta K, Wesenberg F, Einhorn S, Heyman M. Calero Moreno TM, et al. Among authors: heyman m. Leukemia. 2002 Oct;16(10):2037-45. doi: 10.1038/sj.leu.2402697. Leukemia. 2002. PMID: 12357355
Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival.
Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Rosenquist R, Swolin B, Johansson B; Nordic Society of Paediatric Haematology, Oncology (NOPHO); Swedish Cytogenetic Leukaemia Study Group (SCLSG); NOPHO Leukaemia Cytogenetic Study Group (NLCSG). Forestier E, et al. Among authors: heyman m. Br J Haematol. 2008 Mar;140(6):665-72. doi: 10.1111/j.1365-2141.2008.06980.x. Epub 2008 Feb 1. Br J Haematol. 2008. PMID: 18241254 Free article.
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology. Schmiegelow K, et al. Among authors: heyman m. Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17. Blood. 2009. PMID: 19224761 Free PMC article.
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: heyman m. J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171. J Pediatr Hematol Oncol. 2009. PMID: 19648786 Clinical Trial.
615 results